Robert Tep is Managing Director at Diaclone, now part of Medix Biochemica, a global leader in antibodies and immunoassays. With over 30 years of experience in immunology, in pharmaceutical and IVD industries, he has contributed to the development of innovative research tools and diagnostic solutions used worldwide. At Diaclone, he has been involved in advancing monoclonal antibody technologies and supporting collaborations with both academic and industrial partners.
As a member of the Scientific Committee of the Innovative Therapies Days, Robert brings his expertise in immunology, translational research, and industrial applications to help shape a program at the interface of science and biotech innovation.